Immuneering CFO reports 225,000-share ownership

Immuneering Corp executive Andrew Gengos, Chief Financial Officer, reports ownership of 225,000 shares of Class A Common Stock, held directly.

Rhea-AI Filing Summary

Immuneering Corp executive Andrew Gengos, Chief Financial Officer, reports ownership of 225,000 shares of Class A Common Stock, held directly. This disclosure outlines his reported equity stake as an officer and does not list any open-market transactions or derivative positions.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gengos Andrew

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 225,000 shares (Direct)

Key Figures

Shares beneficially owned: 225,000 shares Holding entries reported: 1 Reported buy transactions: 0

3 metrics

Shares beneficially owned 225,000 shares Class A Common Stock held directly by CFO Andrew Gengos

Holding entries reported 1 Number of non-transactional holding rows in this ownership report

Reported buy transactions 0 Open-market purchase transactions included for Andrew Gengos

Key Terms

Class A Common Stock, transaction code, direct or indirect ownership

3 terms

Class A Common Stock financial

"security_title: Class A Common Stock reported for Andrew Gengos"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

transaction code regulatory

"transaction_code_description: Unknown transaction code"

direct or indirect ownership regulatory

"direct_or_indirect uses D/I for Direct/Indirect ownership type"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the insider reporting ownership in Immuneering Corp (IMRX)?

The insider is Andrew Gengos, who serves as Chief Financial Officer of Immuneering Corp. The report reflects his role as an officer and provides details on his equity holdings in the company’s Class A Common Stock.

How many Immuneering (IMRX) shares does CFO Andrew Gengos report owning?

CFO Andrew Gengos reports ownership of 225,000 shares of Immuneering’s Class A Common Stock. These shares are listed as being held directly and represent his reported equity stake in the company as of the referenced date.

Does this Immuneering (IMRX) Form 3 show any insider buying or selling by the CFO?

No, the report does not show any insider buying or selling by the CFO. It records a holding entry only, without any open-market purchase or sale transactions associated with the reported Class A Common Stock.

Are Andrew Gengos’s Immuneering (IMRX) shares held directly or indirectly?

The 225,000 Immuneering shares reported by Andrew Gengos are held directly. The ownership code is listed as direct (D), indicating the shares are not attributed to a trust, fund, or other indirect holding entity.

Does the Immuneering (IMRX) Form 3 disclose any derivative securities for Andrew Gengos?

No, the report lists no derivative securities for Andrew Gengos. The derivative section is empty, indicating there are no options, warrants, or other derivative positions reported alongside his Class A Common Stock holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/16/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gengos Andrew

(Last) (First) (Middle)

245 MAIN STREET

SECOND FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/16/2026

3. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Class A Common Stock	225,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Andrew Gengos	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)